**Echinococcus multilocularis** specific antibody, systemic cytokine, and chemokine levels, as well as antigen-specific cellular responses in patients with progressive, stable, and cured alveolar echinococcosis: A 10-year follow-up

Beate Grüner ID, Lynn Peters ID, Andreas Hillenbrand 2, Patrick Voßberg 3, Jonas Schweiker ID, Elisabeth G. Rollmann 3, Laura H. Rodriguez ID, Jasmin Blumhardt 3, Sanne Burkert ID, Peter Kern 1, Carsten Köhler ID, Peter T. Soboslay ID

1 University Hospital of Ulm, Department of Internal Medicine III, Division of Infectious Diseases, Ulm, Germany, 2 Department of General and Visceral Surgery, Ulm University Hospital, Ulm, Germany, 3 University Clinics Tübingen, Institute for Tropical Medicine, Eberhard-Karls University, Tübingen, Germany

‡ BG and LP share first authorship on this work. CK and PTS are joint senior authors on this work. * peter.soboslay@uni-tuebingen.de

**Abstract**

**Background**

The infestation with **Echinococcus multilocularis** larvae may persist in humans for up to decades without evident clinical symptoms. Longitudinal investigations are needed to understand the dynamic immunological processes in alveolar echinococcosis (AE) patients associated with an active and progressive, a stable or a regressive course of disease.

**Methodology/Principal findings**

This study evaluated the *E. multilocularis* specific antibody responses, systemic cytokine, and chemokine serum levels over a 10-year follow-up period, as well as cellular responsiveness in AE patients. Our results demonstrate a rapid decrease in antibodies against *E. multilocularis* specific antigen Em2+. Especially in cured patients, these antibodies remained negative, making them a significant predictor for cured AE. *E. multilocularis* specific IgG4, and indirect hemagglutination IHA decreased later in time, after around 5 years. While total IgE did not show significant dynamics over the course of disease, *E. multilocularis* specific IgE decreased after one to two years, and increasing levels were a significant predictor of progressive disease. There was no significant change in systemic IL-8, IL-9, CCL18 or CCL20 serum levels over time. Univariate analysis across groups indicated lower IL-8 levels in cured patients; however, this result could not be confirmed by multivariate analysis. Levels of CCL17 decreased during treatment, especially in cured patients, and thus might serve as a predictive or risk factor for progressive disease. Levels of IL-10 and CCL13 decreased during disease, especially after five and ten years of intervention. The *E. multilocularis* antigen (EmAg) inducible cellular productions of MCP1(CCL13), TARC(CCL17) and PARC...
(CCL18) were lowest in patients with cured AE and infection-free controls, while the EmAg inducible cellular production of IFN-γ increased after cure. Significant positive cytokine and chemokine correlations were observed in AE patients for IL-9, IL-10, CCL13(MCP-4), CCL17(TARC) and CCL20(LARC)(for all p < 0.001). *E. multilocularis* specific IgG4 response correlated positively with TARC (p < 0.001). Both markers enhanced over time in progressive disease and decreased after cure. The levels of IL-8, IL-10, MCP4 and LARC enhanced with AE regression.

**Conclusions/Significance**

Repeated biomarker surveys are advisable to evaluate progression or regression of disease during longitudinal follow-up and such analyses can support imaging techniques and improve staging of AE patients.

---

**Author summary**

Alveolar echinococcosis (AE) is a severe disease caused by *Echinococcus multilocularis*, the fox tapeworm. Humans exposed to *E. multilocularis* may develop severe AE with progressive tissue and organ infiltrating growth of the larval stage. The *E. multilocularis* larvae appear to have developed effective immune evasion mechanisms which facilitate an asymptomatic incubation and an extended host and parasite coexistence for decades. Over a 10-year follow-up, this investigation aimed to gain a better understanding of the immunological process associated with an active and progressive, a stable or a regressive course of AE. In summary, the rapid decrease of antibodies against the *E. multilocularis* specific antigen Em2+, especially in cured patients, makes them a significant predictor for cured AE. The positive relation of *E. multilocularis* specific IgG4 responses and chemokine levels of TARC can indicate AE progression when both enhance over time. Enhanced levels of cytokines IL-8, IL-10, and chemokines MCP4 and LARC may predict AE regression. Repeated biomarker surveys are advisable to evaluate progression or regression of AE during longitudinal follow up, and such analyses can support imaging techniques and improve staging of AE patients.

---

**Introduction**

Alveolar echinococcosis (AE) is a severe disease caused by the cestode *Echinococcus multilocularis*, the fox tapeworm. The disease is most prominent in northwest China but also occurs in central Europe [1]. AE morbidity and treatment costs are high, with a lethal course if left untreated [2–5]. Together with cystic echinococcosis, AE is considered a neglected disease [6,7]. Moreover, it is an emerging disease, and an increase in human cases of AE in Europe have been observed over the past decades [2,8–10].

Humans exposed to *E. multilocularis* may develop severe AE with progressive tissue and organ infiltrating growth of the larval stage [11]. *E. multilocularis* larvae may massively proliferate in liver and other organs over decades without evident clinical symptoms, and in this process the evasion and regulatory mechanisms of the parasite play a crucial role on the human host immune response [12–14]. The *E. multilocularis* larvae appear to have developed effective immune evasion mechanisms which facilitate an asymptomatic incubation and an
extended host and parasite coexistence. The larvae may persist for decades exerting a progressive tissue invasive tumour-like growth [1,2,15], but few AE patients may present with a healing course of the disease. This diversity suggested immunological mechanisms which may control the course of AE. Characteristic for a certain resistance to AE is the occurrence of Th1 type cytokines, while elevated production of IL-10 and Th2 cytokines were associated with progressive Em larval growth [16–18].

Only in 10–30% of E. multilocularis seropositive cases [11] clinical disease will develop, suggesting that effective immune responses may have eliminated the larvae when penetrating the intestinal wall at an early stage of infestation [19]. Patients who express Th1-type immune response are more likely able to limit or regress larval growth by forming peri-parasitic granulomas with macrophages and T cells, as well as lesions, or fibrosis and necrosis to encapsulate the parasite [20,21]. Successful immune evasion of the parasite leads to a tolerant Th2 immune response which is unable to prevent the E. multilocularis larval growth [15,22]. The disease spectrum is dependent on an acquired deviation of Th1-related immunity, and the spontaneous secretion of IL-10 by the PBMC was identified as the immunological hallmark of patients with progressive forms of AE involved in the maintenance of tolerance and persistence of the parasite [23–25]. Reactivity of peripheral blood cells to E. multilocularis antigens persisted for years in AE patients after complete resection of the parasitic lesions suggesting that residual parasite tissues will continue to stimulate cellular responses [26]. E. multilocularis may expand regulatory T cell responses [27] and promote a largely Th2-biased response which allows long-term parasite survival, proliferation, and maturation [17,21]. However, only few studies have longitudinally addressed the changes of immunity at different stages of AE in patients.

This investigation aimed to gain a better understanding of the immunological processes at distinct stages of AE disease. Over a 10-year follow-up, antibody responses to E. multilocularis and systemic cytokine and chemokine levels, as well as parasite antigen-specific cellular responses were assessed in patients with progressive, stable, and cured AE. A better understanding of the differences in the elicited immune response may reveal new treatment rationales.

**Material and methods**

**Ethics statement**

All patients gave their written consent to participate in this study, and approval for the latter was obtained from the ethical board at University Clinics of Ulm (Ethik-Kommision Antrag Nr. 71/2004, 71/2004-Amendment2010 and Antrag Nr. 372/2015).

**Alveolar echinococcosis (AE) patients and disease staging**

All AE patients were admitted to and consulted at the Echinococcosis Reference Centre at University Hospitals of Ulm, Germany. The Echinococcosis Centre in Ulm and the University Clinics of Tübingen are in the southwest of the federal state of Baden-Württemberg in Germany, both towns being 70 km apart, in an endemic area for E. multilocularis [25]. The AE patients in the present study were classified into cured, stable, and progressive according to established criteria [3] at the time of the study.

Diagnosis and classification of AE was performed using positive imaging, serology and histology and AE-case-definition according to criteria, which were established by the WHO Informal Working Group on Echinococcosis [28] as well as PNM–staging system (P = parasitic mass in the liver, N = involvement of neighbouring organs, and M = metastasis) [1–3,29], and most patients were re-examined regularly during follow-ups.
The AE patients were staged into progressive, stable and cured AE. The application of imaging techniques for AE staging is essential. Ultrasound (US) and computed tomography (CT) were used to confirm alveolar echinococcosis [1], and magnetic resonance imaging (MRI) can provide a more differentiated diagnosis, to identify blood vessel structures before surgery [3,30]. Positron emission tomography (PET) or combined PET-CT was used to shows areas of high metabolic activity, which may indicate inflammatory reactions and possible activity of the parasite [31].

Clinical status was classified as:

1. cured: patients who underwent curative surgery and showed no signs of residual parasitic mass or relapse for at least two years postoperative.
2. stable disease without BMZ treatment: inoperable patients without benzimidazole treatment who show no signs of progressive disease
3. stable disease with BMZ treatment: inoperable patients on continuous benzimidazole treatment who show no signs of progressive disease
4. progressive disease: inoperable patients with growing parasitic lesion and/or associated biliary or vascular complications despite benzimidazole treatment.

Serum collection from AE patients and healthy controls

Serum samples from AE patients were collected at three-time points; in 2005 (year 1, n = 101 samples), 2010 (year 5, n = 57 samples) and 2016 (year 10, n = 59 samples). Infection-free healthy controls were blood donors (n = 35) from University Clinics of Tübingen; all controls were negative in *E. multilocularis* antigen-specific antibody ELISA responses. For this study, only patients that had donated several times were included to enable cross-time analysis.

**Echinococcus multilocularis** antigen (EmAg) specific IgG responses

Antibody-screening was performed with the Echinococcus-specific IgG indirect hemagglutinin test (IHA) and confirmatory testing was done by the commercialized *E. multilocularis*-specific Em2+-antigen ELISA as described previously [32]. The detection of EmAg-specific IgG1, IgG3, IgG4 and IgE was applied as described previously [33,34].

For analyses of EmAg-specific IgG subclass responses, ELISA microtiter 96 well plates (CORNING; EIA/2 CatNo.3690) were coated overnight at 4˚ C with *E. multilocularis* metacestode larval extract (EmAg, 12 μg/ml) in phosphate-buffered saline (PBS). For *E. multilocularis* antigen (EmAg) preparation, solid metacestode tissues were isolated from metacestode-infected mongolian gerbils (*Meriones unguiculatus*), tissues were washed in phosphate-buffered saline (PBS, pH 7.2–7.4) and ground on ice in a Ten-Broek tissue grinder until a homogeneous liquid extract appeared. The antigen suspension was then sonicated twice on ice for 10 min (30% cycle, Model 250, Branson Ultrasonics, Danbury, USA). The liquid extract was then collected and centrifuged at 15,000 g for 30 min at 4˚ C. The supernatant was sterile-filtered (0.22 μm) and stored in aliquots at -70˚ C for further use. The protein concentration of these *E. multilocularis* antigens was determined using the bicinchoninic acid protein determination kit (Pierce, Rockford, IL, USA). After coating, ELISA plates were washed twice with PBS 0.05% Tween 20 (PBST, pH 7.4) and subsequently blocked with PBS containing 5% BSA for 1.5 hours at 37˚ C. For the analyses of antibody responses IgG1, IgG3 and IgG4 were selected because the carbohydrate rich antigens located on the laminated layer of metacestode larvae will trigger these IgG subclasses. Serum samples from AE patients and echinococcosis-free controls were diluted 1:10 with 5% BSA in PBS, added to each well and incubated at 37˚ C for
2 hours. Then plates were washed three times and detection was performed with monoclonal anti-human IgG1, IgG3, or IgG4 antibody conjugated with HRP (Thermo Fisher, A-10648, A-10654, 05–3600) diluted 1:500 with 5% BSA in PBS and added for 1.5 hours at 37˚ C. After three times washing, Tetramethylbenzidine (TMB) solution was added, and colour reaction was stopped with 0.5 M sulfuric acid. Optical density of sample wells was determined at 450 nm using the EL808 Photometer (BIOTEK) and Gen5 1.11 software. The data were processed and statistically evaluated with JMP 14.2.0.

**Isolation of PBMC, cell culture experiments and determination of cytokine and chemokine production**

Peripheral mononuclear blood cells (PBMC) from AE patients were isolated by Ficoll gradient centrifugation and cultured *in vitro* as previously described [35]. Briefly, PBMC were adjusted to 1x10^7/ml in RPMI supplemented with 25 mM HEPES buffer, 100 U/ml penicillin, 100 mg/ml streptomycin and 0.25 mg/ml amphotericin B. Freshly isolated PBMC were cultured at 2.5x10^6 PBMC/ml in RPMI (as above) and stimulated with *E. multilocularis* metacestode antigen extract (EmAg, 50 μg/ml) or remained without stimulation (baseline) for 48h in 5% CO2 at 37˚ C and saturated humidity. Cell culture supernatants were collected after 48h and stored below –70˚ C until further use. Cytokine and chemokine secretion by stimulated PBMC was quantified by sandwich enzyme-linked immunosorbent assay (ELISA) using monoclonal and polyclonal antibodies for interleukin(IL) - 8 (IL-8, CXCL8), IL-9, IL-10, interferon-gamma (IFN-γ), and the CC chemokines MCP-1 (CCL2), MCP-3 (CCL7), MCP-4 (CCL13), TARC (CCL17), PARC (CCL18) and LARC (CCL20) as recommended by the manufacturers and described previously [34–36]. The detection limits of the cytokine and chemokine ELISAs (DuoSet, R&D Systems, Minneapolis, USA) were at 50 pg/ml.

**Data analysis**

Statistical analysis was performed using IBM SPSS version 25. All variables were described with mean, median and standard deviation. Prior to every calculation, variables were tested for normal distribution using graphical methods such as histogram, P-P- and Q-Q-plot as well the Shapiro-Wilk test. Skewed data was log-transformed for further analysis. To assess changes in serological markers and cytokine levels over time, repeated-measures ANOVA, and paired t-test for normally distributed or Wilcoxon signed-rank test for non-parametric data were used. Comparisons across groups were conducted with ANOVA and independent t-test for normally distributed, continuous data and Mann-Whitney-test for non-normally distributed, continuous variables. For categorical variables, the Chi-square test or Fisher’s exact test (if appropriate) were used. Results were stated as mean and standard deviation in case of normally distributed data and as median, 25th and 75th percentile for non-normally distributed data. Correlations were performed according to Pearson (continuous variables) or Spearman (non-continuous variables). To evaluate the effect on the clinical status while adjusting for confounders and interactions between variables, a multivariate analysis was conducted. Two logistic regression models, one for progressive disease at any point in time and one for cured disease at baseline were designed. With respect to the sample size, a maximum of ten variables was included into the model to prevent over-fitting. Before the final model was established, a screening for multicollinearity was conducted, excluding variables with a variance inflation factor (VIF) of 10.0 or higher. Prior to the multivariate analysis, multiple imputation was performed to adjust for missing dependant variables. As many auxiliary variables and cases as possible were added to the imputation process to produce an accurate dataset. The number of data sets generated was determined using the formula suggested by Newgard and Haukoos
aiming for a relative efficiency of at least 95%, which is considered a high rate. Results were considered significant with a p-value (probability to make a type I error) smaller than 5%.

The statistical package JMP 14.2.0 was used for analyses of chemokine serum levels and the cellular production of cytokines and chemokines in patients with progressive, stable and cured AE. Significant differences between groups were determined with Tukey’s test after logarithmic transformation to stabilize the variance of data, either of the brut production (chemokine concentration in supernatants), or the net production (brut production minus chemokine concentration of resting PBMC (baseline)). The net productions were calculated according to the following formula: 

\[
\text{production index} = \frac{\text{brut production} + 1}{\text{baseline production} + 1}
\]

We added one to the numerator and the denominator because of zero values in baseline and brut productions. For multiple comparisons, and to avoid type I errors, differences between infection groups were analyzed by the Tukey test. Bonferroni adjustment was applied, P values below \(p < 0.001\) are considered.

Results

Timetable of follow-up of clinical examinations of AE patients

AE patients’ follow-up visits were conducted at different points in time as displayed in Table 1. Of 63 patients at baseline, 12 patients could be follow-up for a mean of 11.3 years.

*Echinococcus* IgG indirect hemagglutinin test (IHA) results in AE patients over time

Table 2 demonstrates the different levels of IgG IHA at different points in time. As many patients did not show elevated IgG IHA levels (coded as ‘0’) medians were therefore ‘0’. To display more subtle differences between groups, the respective mean and standard deviation were used as auxiliary variables in spite of the non-normal distribution A Wilcoxon test was performed to conduct group wise comparisons between baseline and follow-up visits. Only after a mean of 5 years (Visit 4) there was slight evidence \((p = 0.05)\) that there was a significant decrease of IgG levels over time. The results displayed in Table 2 indicate a decrease in IgG IHA levels compared to baseline \((p = 0.05)\) with a moderate Cohen’s effect size \((r = 0.27)\). This difference became clearer comparing IgG IHA levels after six months and five years \((Z = -2.092, N = 23, p = 0.036)\) with a strong Cohen’s effect size of 0.44.

*E. multilocularis* Em2+ antigen specific IgG responses in AE patients over time

Antibodies against Em2+ were measured as dichotomous variable. At baseline \((V_0)\), these antibodies were detected in 67 of 100 patients. Regarding the follow-up visits, a one-sided

| \(V_x\) | \(N\) | \(\Delta t_{V_x-V_0}\) |
|-------|------|------------------|
| \(V_0\) | 63 | - |
| \(V_1\) | 40 | 5.3 ± 1.9 months |
| \(V_2\) | 43 | 11.7 ± 2.1 months |
| \(V_3\) | 13 | 23.2 ± 5.5 months = 1.5 ± 0.7 years |
| \(V_4\) | 52 | 65.4 ± 8.8 months = 5.1 ± 0.9 years |
| \(V_5\) | 12 | 141.3 ± 8.9 months = 11.3 ± 0.7 years |

https://doi.org/10.1371/journal.pntd.0010099.t001
binominal test was conducted to evaluate if the observed distribution of detectable Em2+ antibodies differed from the expected distribution (0.67) at the different points in time. The results are displayed in Table 3. Overall, the percentage of patients with antibodies against Em2+ was lower upon follow-up visits compared to baseline. At V₁ and V₂ the observed and expected distribution differed significantly. At V₃ and V₅ sample size was too small and at V₄ the effect size was insufficient to yield significant results. Detectable antibodies against Em2+ correlated with a higher level of Echinococcus IgG IHA (s = 0.343, p = 0.001).

**E. multilocularis** antigen specific IgG4 responsiveness in AE patients over time

Table 4 demonstrates the IgG4 responses (OD) to larval extract of *E. multilocularis* (EmAg) over the course of study. Paired t-tests were conducted with the subgroups V₀, V₁ and V₄, e.g. at baseline, after around five months and five years. The sample size in the remaining subgroups did not meet criteria of a power level of at least 0.8 and were hence not included in further analysis. Compared to baseline, levels of IgG4 EmAg decreased over time. This effect was significantly after around five years (p = 0.028) with a moderate Cohen’s effect size (r = 0.37). The decrease between V₁ and V₄ was not significant (t(21) = 0.975, p = 0.341).

Levels of total IgE and *E. multilocularis*-specific IgE in AE patients over time

Table 5 shows the level of total and *E. multilocularis*-specific levels of IgE at different points in time. A paired t-test was conducted to assess differences between baseline values and the IgE levels at respective points in time. Since levels of specific IgE were measured either on V₂ or V₃ in most cases, these subgroups were merged for the following analysis. Hence, the numbers in

| Vₓ | N  | M      | SD | MD, 1xx | P₂₅-P₇₅ | Min | Max   | Z     | p    |
|----|----|--------|----|---------|----------|-----|-------|-------|------|
| V₀ | 63 | 98.1   | 293.95 | 0.0 | 0.0–31.5 | 0.0 | 2048.0 | -     | -    |
| V₁ | 37 | 111.7  | 344.20 | 0.0 | 0.0–81.5 | 0.0 | 2048.0 | -0.566 | 0.572 |
| V₂ | 43 | 87.1   | 203.27 | 0.0 | 0.0–32.0 | 0.0 | 1024.0 | -0.462 | 0.644 |
| V₃ | 12 | 125.33 | 291.84 | 32.0 | 0.0–64.0 | 0.0 | 1024.0 | -0.954 | 0.340 |
| V₄ | 51 | 82.88  | 203.27 | 0.0 | 0.0–0.0 | 0.0 | 512.0 | -1.959 | 0.050*|
| V₅ | 12 | 164.92 | 566.11 | 0.0 | 0.0–16.0 | 0.0 | 2048.0 | 0.000  | 1.000 |

https://doi.org/10.1371/journal.pntd.0010099.t002

Table 3. Number and percentage of AE patients with detectable Em2+ antibodies at different visits and significance level in binominal test. Vₓ = follow-up visit with V₀ = baseline, N(%) = total number (percentage of patients) with detectable Em2+, p-value = significance level with * considered significant.

| Vₓ | N(%) | p   |
|----|------|-----|
| V₀ | 67 (67.0%) | - |
| V₁ | 18 (50.0%) | 0.040* |
| V₂ | 22 (51.2%) | 0.023* |
| V₃ | 6 (50.0%) | 0.171 |
| V₄ | 31 (60.8%) | 0.212 |
| V₅ | 7 (53.8%) | 0.233 |

https://doi.org/10.1371/journal.pntd.0010099.t003
V$_{2/3}$ represent specific IgE levels around one to two years after baseline measurements. At V$_5$, no measurements of specific IgE levels were conducted. While no significant alteration in total IgE can be found over the course of disease, mean and median values have a decreasing tendency over time. There is a significant decrease in specific IgE after one to two years with a moderate Cohen’s effect size (0.31). There was a positive correlation between Echinococcus IgG IHA and total IgE ($s = 0.549, p < 0.001$).

Cytokine and chemokine serum levels in AE patients over time

Cytokine levels are displayed in Table 6. Log transformation of values was performed prior to further analysis. For IL-8, IL-9, CCL18 and CCL20, no significant changes between baseline and the follow-up visits were found (paired t-test). Levels of IL-10 were significantly lower at V$_4$ ($t(49) = 4.078, p < 0.001$) and V$_5$ ($t(11) = 4.052, p = 0.002$) comparing to baseline, reflecting a significant decrease after five and ten years. The further decrease of IL-10 levels between five and ten years after baseline was again significant ($t(6) = 2.554, p = 0.043$). The decrease in CCL13 was highly significant after 5 years ($t(49) = 5.151, p < 0.000$) and ten years ($t(11) = 3.278, p = 0.007$). Compared to baseline, levels of CCL17 were significantly lower after five years ($t(48) = 2.915, p = 0.005$) and ten years ($t(12) = 3.025, p = 0.011$) compared to baseline. Levels seem to increase again between five and ten years after baseline ($t(7) = -2.403, p = 0.047$), however, the sample size was small and the difference barely significant.

### Table 4. Reactivity (indicated as optical densities OD) of IgG4 to larval extract of E. multilocularis (EmAg) over time and difference of respective levels compared to baseline. Vx = follow-up visit with V0 = baseline, N = number, M = mean, MD = median, SD = standard deviation; Min. = minimum, Max. = maximum, t = difference in units of standard error, df = degrees of freedom, p-value = significance level with * considered significant.

| Vx   | N  | M    | MD  | SD  | Min  | Max  | t(df) | p   |
|------|----|------|-----|-----|------|------|-------|-----|
| V0   | 84 | 0.560| 0.626| 0.337| 0.054| 1.2  | -     | -   |
| V1   | 36 | 0.558| 0.625| 0.283| 0.064| 0.978| 0.896(34)| 0.376|
| V2   | 9  | 0.419| 0.429| 0.280| 0.102| 0.919| -     | -   |
| V3   | 1  | 1.105| 1.105| -    | 1.105| 1.105| -     | -   |
| V4   | 43 | 0.373| 0.226| 0.345| 0.049| 1.211| 3.298(33)| 0.002*|
| V5   | 7  | 0.510| 0.353| 0.437| 0.060| 1.068| -     | -   |

https://doi.org/10.1371/journal.pntd.0010099.t004

### Table 5. Levels of total and E. multilocularis-specific IgE in kU/l over time and difference of respective levels compared to baseline. Vx = follow-up visit with V0 = baseline, N = number, M = mean, MD = median, SD = standard deviation; Min. = minimum, Max. = maximum, t = difference in units of standard error, df = degrees of freedom, p-value = significance level with * considered significant.

| Vx   | N  | M    | MD  | SD  | Min  | Max  | t(df) | p   |
|------|----|------|-----|-----|------|------|-------|-----|
| Levels of total IgE in kU/l |
| V0   | 106| 474.0| 77.5| 1,283.5| 1.0| 1,1150.0| -     | -   |
| V1   | 40 | 377.2| 51.4| 875.4 | 3.3| 4,765.0 | -0.512(38)| 0.612|
| V2   | 43 | 330.1| 49.9| 754.5 | 0.0| 4,373.0 | -0.216(41)| 0.830|
| V3   | 13 | 136.0| 84.4| 218.9 | 9.5| 841.0  | -0.475(12)| 0.643|
| V4   | 51 | 296.3| 63.3| 926.2 | 1.1| 6,286.0| -0.024(48)| 0.981|
| V5   | 12 | 407.6| 63.6| 792.7 | 2.5| 2,363.0| -1.049(10)| 0.319|

| Levels of specific IgE in kU/l |
| V0   | 76 | 2.1  | 0.5 | 4.5  | 0.00| 24.1  | -     | -   |
| V1   | 19 | 0.00 | 0.00| 0.00 | 0.00| 0.00  | 1.000(18)| 0.331|
| V2/3 | 48 | 1.4  | 1.6 | 2.7  | 0.00| 15.0  | 2.127(47)| 0.035*|
| V4   | 36 | 1.6  | 0.4 | 3.0  | 0.00| 12.7  | 0.050(34)| 0.961|

https://doi.org/10.1371/journal.pntd.0010099.t005

Echinococcus multilocularis infested patients’ timely changes of immunity
Table 6. Levels of cytokines and chemokines over time.

Echinococcus multilocularis infested patients’ timely changes of immunity

For the analyses of EmAg specific IgG isotype responses, 217 blood samples were collected from AE patients over time. Vx = follow-up visit with V0 = baseline, N = number, M = mean, SD = standard deviation; Min. = minimum, Max. = maximum.

| Vx  | N  | IL-8(CXCL8) | IL-9 |
|-----|-----|-------------|------|
|     |     | M           | MD   | SD   | Min | Max | M     | MD   | SD   | Min | Max |
| V0  | 108 | 175.6       | 0.0  | 1,558.1 | 0.0 | 1,619.0 | 44.8 | 0.0  | 128.3 | 0.0 | 930.4 |
| V1  | 36  | 16.4        | 0.0  | 69.6    | 0.0 | 417.0    | 73.1 | 0.0  | 135.9 | 0.0 | 502.4 |
| V2  | 9   | 89.7        | 0.0  | 269.0   | 0.0 | 807.0    | 180.4 | 0.0  | 328.3 | 0.0 | 970.4 |
| V3  | 1   | 0.0         | 0.0  | -      | 0.0 | 0.0      | 0.0  | 0.0  | -     | 0.0 | 0.0  |
| V4  | 50  | 24.3        | 0.0  | 137.2   | 0.0 | 966.0    | 73.4 | 0.0  | 319.4 | 0.0 | 1,902.7 |
| V5  | 12  | 2,551.6     | 0.0  | 8,272.6 | 0.0 | 28,767.0 | 0.0  | 0.0  | 0.0  | 0.0 | 0.0  |

| Vx  | N  | MCP-4(CCL13) | TARC(CCL17) |
|-----|-----|--------------|-------------|
|     |     | M            | MD          | SD   | Min | Max | M     | MD   | SD   | Min | Max |
| V0  | 108 | 333.6        | 176.5       | 442.9 | 6.0 | 2,757.0 | 480.3 | 205.0 | 812.3 | 0.0 | 4,825.0 |
| V1  | 36  | 364.5        | 321.5       | 310.9 | 25.0 | 2,665.0 | 562.0 | 332.0 | 705.1 | 0.0 | 3,571.0 |
| V2  | 9   | 531.9        | 265.0       | 857.4 | 55.0 | 766.0  | 527.3 | 167.0 | 1,005.9 | 0.0 | 3,303.0 |
| V3  | 1   | 237.0        | 237.0       | -    | 237.0 | 237.0  | 448.0 | 448.0 | -     | 448.0 | 448.0 |
| V4  | 50  | 117.0        | 66.5        | 143.1 | 0.0 | 812.0  | 114.7 | 17.0 | 277.0 | 0.0 | 1,468.0 |
| V5  | 12  | 227.8        | 114.0       | 400.9 | 18.0 | 1,468.0 | 386.6 | 185.0 | 528.6 | 0.0 | 1,523.0 |

E. multilocularis patients with progressive, stable and cured AE

For the analyses of EmAg specific IgG isotype responses, 217 blood samples were collected from AE patients (Table 7). The AE patients were staged into three groups: those with progressive AE, with stable and cured AE. At year 1 of the study, the proportion of patients staged with progressive AE disease was 21.8%, in year 5 it reduced to 7% and in year 10 to 8.5%. The proportion of patients with cured AE increased from year 1 with 17.8% to 24.6% and 28.8% in year 5 and year 10, respectively. Patients with stable AE comprised the largest group (n = 137) and with 60%, 62% and 68% the proportion of AE stable remained similar at the three time points of study (Table 7).

E. multilocularis antigen (EmAg) specific IgG isotype responses

The EmAg specific IgG responses were highest with progressive, lower in stable and lowest in cured AE patients (Fig 1). The EmAg-specific IgG1 responses were significantly higher with
progressive (p = 0.0001) and stable (all ages) (p ≤ 0.0001) than in cured AE patients (Fig 1, Part A). Similarly, the EmAg-specific IgG3 responses were highest with progressive, lower with stable (all ages) and lowest in cured AE patients, without significant differences between the study groups (Fig 1, Part B; Tukey Kramer Test). The EmAg specific IgG4 responses in progressive and stable (≥ 60y) AE patients were significantly higher (p < 0.0001) than in cured AE patients (Fig 1, Part C). In cured AE patients, IgG4 responses were significantly lower (p < 0.0001) than at the progressive, stable (all age groups) and stable (≥ 60y) stage of disease (Fig 1, Part C). In infection-free controls, IgG4 reactivity was slightly lower than in cured AE patients.

For the determination of age dependent EmAg specific IgG4 responses, the patients were grouped in five age groups (Fig 1, Part D). The youngest age group of patients up to 30 years showed the lowest and the 61–75 years old patients the highest IgG4 reactivity. Up to the age of 61–74 years the mean OD values increased steadily, but in the oldest patients (76+ years) slightly lower IgG4 responses to EmAg were measured. Significantly different EmAg-specific IgG4 responses (p = 0.041) were found between the age groups of 0–30 and 61–75 years. In younger stable AE patients (≤ 60y) the EmAg-specific IgG4 responses were measured lower than in older stable (≥ 60y) AE patients (p = 0.021).

Chemokine serum levels in patients with progressive, stable and cured AE

Pro-inflammatory IL-8(CXCL8), regulatory IL-10 and TH-2 type IL-9 cytokines were measured in serum samples of AE patients and infection-free controls using specific ELISA (Table 8). The neutrophil-activating protein IL-8 concentrations were lowest in progressive and stable AE patients, enhanced in controls, and highest in cured AE patients, and differences did not attain significance. The Th2-type cytokine IL-9 levels were highest in stable (≥ 60y) AE patients, slightly lower in progressive AE, older stable (≥ 60y) and cured AE cases and at similar levels as measured in infection-free controls (Table 8). The regulatory cytokine IL-10 serum levels were highest in controls and younger (≤ 60y) AE patients, and less in progressive stable (≥ 60y) and cured AE case.

The CC chemokines TARC(CCL17), PARC(CCL18) and LARC(CCL20) were measured in serum samples of AE patients and infection-free controls (Table 8). Tissue and activation regulated chemokine CCL17(TARC) levels in sera steadily diminished from progressive to stable and cured AE patients, while being highest in controls. Pulmonary and activation regulated chemokine CCL18(PARC) serum concentrations were equally high (≥ 10,000 pg/ml) in AE patient groups and controls. Liver and activation regulated chemokine CCL20(LARC) was

### Table 7. Alveolar echinococcus (AE) patients staged into groups with progressive, with stable and cured disease.

The mean age with minimum and maximum ist indicated in brackets. The average age was 58.7 years. The two youngest patients were 19, the oldest patient 106 years old. One third of the patients were between 61 and 75 years old at the time of blood collection, and 31% percent of the patients were female. The youngest age group (0–30years) was the smallest with 8%, and the higher age groups of 31–45y, 46–60y, 61–75y and 76+y represented 16%, 24%, 36% and 16% of all AE patients, respectively.

| AE Progressive | AE Stable | AE Cured | N  |
|---------------|-----------|----------|----|
| Year 1        |           |          |    |
| [63.8y (56;70)] | [53.9y (23;76)] | [59.1y (26; 106)] | 101  |
| Year 5        |           |          |    |
| [65y (65; 65)] | [48.4y (28; 74)] | [51.7y (30; 75)] | 57   |
| Year 10       |           |          |    |
| [54.2y (19;76)] | [61.5 (32; 89)] | [59.1y (30; 80)] | 59   |
| Total         | 31 (14%)  | 137 (63) | 49 (23%) | 217  |

https://doi.org/10.1371/journal.pntd.0010099.t007

Echinococcus multilocularis infested patients’ timely changes of immunity
Fig 1. The *E. multilocularis* antigen-specific IgG reactivity (OD) in alveolar echinococcosis (AE) patients and infection-free controls. The AE patients were staged into those with progressive AE, with stable (<60y), stable (≥60) and cured AE. For the determination of age dependent EmAg specific IgG4 responses, the patients were grouped in five age groups. Blood samples from AE patients were collected at three time points in 2005 (year 1) in 2010 (year 5) and in 2016 (year 10). Controls were echinococcosis infection-free healthy blood donors. In (A) the EmAg specific IgG1, in (B) the EmAg specific IgG3 and in (C) the EmAg specific IgG4 responses are shown as mean optical densities (OD) with the 95% confidence intervals for the means (diamonds). The data presented in box plots show the median OD per group with the 25% and 75% quartiles and the 1.5x of the interquartile range with outlier as individual points. In (D) the IgG4 reactivity in AE patients to EmAg is shown as mean OD per age group with the 95% confidence intervals.

https://doi.org/10.1371/journal.pntd.0010099.g001
similarly low in all patient groups, but significantly higher in controls than in cured AE patients.

**E. multilocularis** antigen-induced cellular cytokine and chemokine production

To study the chemokine (MCP-1, MCP-3, MCP-4, PARC, and TARC) and cytokine (IL-10, IFN-γ) production induced by *E. multilocularis* antigen (EmAg), PBMCs from AE patients were stimulated and the release of cytokines and chemokines into cell culture supernatants was quantified by specific ELISA (Fig 2). The monocyte chemoattractant MCP-1 production by PBMC was significantly higher in patients with progressive than in stable (p = 0.0006) and cured (p = 0.0002) patients (Fig 2, Part A). MCP-3 cellular production was slightly higher with progressive than stable AE patients (p = 0.03). No differences were observed for MCP-4 between the AE patient groups. The EmAg inducible IL-10 release was highest in patients with stable AE, and less in patients with vital/progressive or cured AE, and differences did not attain significance. The EmAg-stimulated cellular release of IFN-γ by PBMC was significantly lower in patients with progressive and stable AE (p < 0.01) than in infection-free controls (Fig 2, Part B). The activation regulated chemokines TARC(CCL17), and PARC(CCL18) were produced lowest by PBMC from cured AE patients and infection-free controls (for TARC p < 0.01 versus controls) (Fig 2, Part C).

**Correlations of cytokines and chemokines**

Paired sample correlations of parameters in AE patients. The EmAg IgG4 responses correlated positive (R = 0.425, p < 0.0001) with an enhancing AE disease severity (stage 1–4). The EmAg-specific IgG4 reactivity associated weakly with age (R = 0.22; p = 0.056) (Table 9) and the patients’ age did not correlate with the AE disease severity stages. Significant positive cytokine and chemokine correlations were observed in AE patients for IL-8 and IL-9 with TARC(CCL17) and LARC(CCL20), and for IL-10 with IL-8, IL-9, MCP-4(CCL13), TARC, LARC and PARC (for all p < 0.001). Negatively correlated were cytokines IL-8, IL-9, IL-10, and chemokines MCP-4, TARC and LARC with the study years. Solely TARC correlated positive with the EmAg-specific IgG4 responses (R = 0.24, p = 0.0011). With the AE disease status negatively correlated were IL-8 (R = -0.462, p < 0.0001), IL-10 (R = -0.157, p = 0.013), MCP-4 (R = -0.142, p = 0.024) and LARC (R = -0.262, p < 0.0001).

---

Table 8. Serum concentrations of cytokines and chemokines. Cytokines IL-8, IL-9 and IL-10 and chemokines MCP-4(CCL13), TARC(CCL17), PARC(CCL-18), LARC(CCL20) concentrations in pg/ml (mean [min, max]) were quantified by specific sandwich ELISA. The alveolar echinococcosis (AE) patients were staged in 4 groups with progressive, stable with equal or younger than 60 years (<60y), stable older than 60 years (>60), and patients with cured AE. Control individuals were *E. multilocularis* infection-free. For IL-8: "Tukey-Kramer Test: p = 0.04 Cured vs. Control and vs. Stable and vs. Vital/Progressive; For LARC(CCL20) **Tukey-Kramer Test: p = 0.001 for Cured vs. Control.

| AE Study Group | n | IL-8(CXCL8) (pg/ml) [min;max] | IL-9 | IL-10 | MCP-4 (CCL13) | TARC (CCL17) | PARC (CCL18) (ng/ml) | LARC (CCL20) |
|----------------|---|-----------------------------|-----|------|---------------|--------------|----------------------|-------------|
| Progressive    | 31 | 2 [0; 29]                  | 66 [0; 1,186] | 153 [0; 1,991] | 226 [15; 1,391] | 545 [0; 2,115] | 100 [0; 200] | 79 [0; 1,560] |
| Stable (<60y)  | 35 | 41 [0; 966]               | 98 [0; 1,903] | 699 [0; 7,586] | 307 [6; 2,2529] | 357 [0; 2,558]  | 97 [0; 200]  | 135 [0; 1,812] |
| Stable (≥60)   | 36 | 37 [0; 417]               | 31 [0; 378]  | 311 [0; 3,606] | 266 [18; 1,117] | 284 [0; 2,641] | 100 [0; 300] | 149 [0; 2,353] |
| Cured          | 49 | 969 [0; 2,8768]*          | 23 [0; 274]  | 223 [0; 2,698] | 224 [0; 1,468]  | 215 [0; 1,523] | 100 [0; 200] | 65 [0; 1,193]  |
| Control        | 35 | 318 [0; 2,015]           | 46 [0; 775]  | 709 [0; 8,572] | 515 [101; 1,978] | 687 [1; 2,785] | 200 [0; 500] | 641 [0; 4,110]** |

https://doi.org/10.1371/journal.pntd.0010099.t008
Fig 2. The *E. multilocularis* antigen inducible cellular production by PBMCs of chemokines and cytokines. In (A) MCP-1(CCL2), MCP-3(CCL7), MCP-4(CCL13), in (B) cytokines IL-10 and IFN-γ and in (C) chemokines CCL17(TARC) and CCL18(PARC) were investigated in patients with progressive, stable, and cured AE, and in *E. multilocularis* infection-free controls. Freshly isolated and *in vitro* cultured PBMCs (2.5x10^6/ml) were stimulated with *E. multilocularis* antigen (EmAg, 12 μg/ml) or remained without stimulation (baseline) for 48 hours. Cytokines and chemokines secreted into cell culture supernatants were quantified with specific ELISA. The concentrations are indicated as mean (net) amounts in pg/ml (with the 5% upper and 95% lower confidence interval) of cytokine or chemokine released from stimulated PBMC minus the cellular production of unstimulated (baseline) PBMC. MCP-1(CCL2), MCP-3(CCL7) and MCP-4(CCL13) production by PBMC was quantified in AE patients with progressive (n = 7) stable (n = 29) and cured disease (n = 10) disease. For IL-10, IFN-γ and PARC(CCL18) and TARC(CCL17) production was investigated in AE patients with progressive (n = 19), stable (n = 27) and cured disease (n = 14), and in *E. multilocularis* infection-free controls (n = 6).* *p < 0.01 versus cured or control.

https://doi.org/10.1371/journal.pntd.0010099.g002

Table 9. Paired Correlations of serum levels of cytokines and chemokines (in pg/ml) in AE patients, with age (in years), EmAg-specific IgG4 responses (OD values), stage of AE disease (1:progressive, 3:stable, 2:cured; 1:control) (study groups: n = 217 AE patients, n = 30 infection-free controls) and year of sample collection (year 1, 5, 10) are shown.

| Variable 1               | Variable 2               | Correlation | pairs N | lower 95% CI | upper 95% CI | p      |
|--------------------------|--------------------------|-------------|---------|--------------|--------------|--------|
| AE Disease Status (1–4)  | IgG4 EmAg (OD)           | 0.4259      | 185     | 0.3001       | 0.5371       | <.0001 |
| AE Disease Status (1–4)  | Study Year (1,5,10)      | -0.1738     | 217     | -0.3001      | -0.0416      | 0.0103 |
| Age (y)                  | IgG4 EmAg (OD)           | 0.2116      | 82      | -0.0056      | 0.4098       | 0.0563 |
| Age (y)                  | AE Disease Status (1–4)  | -0.0962     | 105     | -0.2827      | 0.0972       | 0.3288 |
| Age (y)                  | Study Year (1,5,10)      | 0.0548      | 105     | -0.1383      | 0.2439       | 0.5787 |
| IL-8 [pg/ml]             | LARC(CCL20)              | 0.5431      | 247     | 0.4487       | 0.6255       | <.0001 |
| IL-8                     | AE Disease Status (1–4)  | -0.4629     | 247     | -0.5556      | -0.3588      | <.0001 |
| IL-8                     | TARC(CCL17)              | 0.3602      | 245     | 0.246        | 0.4645       | <.0001 |
| IL-8                     | Study Year (1,5,10)      | 0.1485      | 217     | 0.0156       | 0.2762       | 0.0288 |
| IL-9 [pg/ml]             | LARC(CCL20)              | 0.4761      | 247     | 0.3735       | 0.5672       | <.0001 |
| IL-9                     | MCP-4(CCL13)             | 0.4          | 247     | 0.3115       | 0.5177       | <.0001 |
| IL-9                     | Study Year (1,5,10)      | -0.3336     | 217     | -0.4469      | -0.2097      | <.0001 |
| IL-9                     | IL-8                     | 0.2545      | 247     | 0.1339       | 0.3676       | <.0001 |
| IL-9                     | TARC(CCL17)              | 0.2483      | 245     | 0.1269       | 0.3623       | <.0001 |
| IL-10 [pg/ml]            | IL-8                     | 0.3795      | 247     | 0.2673       | 0.4815       | <.0001 |
| IL-10                    | IL-9                     | 0.4841      | 247     | 0.3824       | 0.5742       | <.0001 |
| IL-10                    | MCP-4(CCL13)             | 0.6874      | 247     | 0.6154       | 0.748        | <.0001 |
| IL-10                    | PARC(CCL18)              | 0.2226      | 247     | 0.1005       | 0.338        | 0.0044 |
| IL-10                    | TARC(CCL17)              | 0.2844      | 245     | 0.165        | 0.3957       | <.0001 |
| IL-10                    | LARC(CCL20)              | 0.5536      | 247     | 0.4607       | 0.6346       | <.0001 |
| IL-10                    | Study Year (1,5,10)      | -0.2244     | 217     | -0.3472      | -0.094       | 0.0009 |
| IL-10                    | AE Disease Status (1–4)  | -0.1576     | 247     | -0.2769      | -0.0334      | 0.0132 |
| MCP-4(CCL13)             | LARC(CCL20)              | 0.5592      | 247     | 0.467        | 0.6394       | <.0001 |
| MCP-4(CCL13)             | PARC(CCL18)              | 0.0944      | 247     | 0.0765       | 0.3163       | 0.0016 |
| MCP-4(CCL13)             | TARC(CCL17)              | 0.439       | 245     | 0.3319       | 0.5349       | <.0001 |
| MCP-4(CCL13)             | IL-8                     | 0.3905      | 247     | 0.2793       | 0.4914       | <.0001 |
| MCP-4(CCL13)             | Study Year (1,5,10)      | -0.2536     | 217     | -0.3741      | -0.1246      | 0.0002 |
| MCP-4(CCL13)             | AE Disease Status (1–4)  | -0.1435     | 247     | -0.2636      | -0.019       | 0.0241 |
| TARC(CCL17)              | LARC(CCL20)              | 0.3593      | 245     | 0.245        | 0.4638       | <.0001 |
| TARC(CCL17)              | IgG4 EmAg (OD)           | 0.2414      | 180     | 0.0986       | 0.3745       | 0.0011 |
| TARC(CCL17)              | Study Year (1,5,10)      | -0.1762     | 215     | -0.3028      | -0.0434      | 0.0096 |
| LARC(CCL20)              | AE Disease Status (1–4)  | -0.2625     | 247     | -0.3751      | -0.1424      | <.0001 |
| LARC(CCL20)              | Study Year (1,5,10)      | -0.1382     | 217     | -0.2665      | -0.0051      | 0.042  |

https://doi.org/10.1371/journal.pntd.0010099.t009
Unpaired Pearson’s correlations of cytokine and chemokine levels in AE patients. Significant positive cytokine and chemokine correlations (Table 10) were observed in AE patients for IL-9 with IL-10, CCL13(MCP-4), CCL17(TARC) and CCL20(LARC), for IL-10 with CCL13, CCL17 and CCL20, for CCL13 with CCL17 and CCL20, and for CCL17 with CCL20 (for all $p < 0.001$). Higher levels of EmAg specific IgG4 correlated with lower levels of CCL17 ($r = -0.246$, $p = 0.025$) and CCL18 ($r = 0.428$, $p < 0.001$).

Associations with clinical status
Both serological markers, *Echinococcus* IgG IHA and antibodies against Em2+ differed between the respective clinical groups (Kruskal-Wallis-test, $X^2_{\text{IHA}}(3) = 10.037$, $p = 0.018$; $X^2_{\text{Em2}}(3) = 19.341$, $p < 0.000$). Mean ranks in both *Echinococcus* IgG IHA and Em2+ tended to increase from cured (31.0/30.6), stable without BMZ therapy (43.3/34.9), stable with BMZ therapy (55.5/55.7) to progressive disease (52.3/67.0).

IL-8 differed significantly between the clinical groups (one-way ANOVA) ($F(3) = 3.070$, $p = 0.031$). Cured patients showed significantly higher levels of IL-8 ($M = 1619.1$ pg/ml) than those stable with ($M = 28.6$ pg/ml) or without BMZ therapy ($M = 29.1$ pg/ml).

CCL17 levels tended to be lower in those cured ($M = 103.60$) compared to those stable without ($M = 301.93$) or with BMZ therapy ($M = 557.63$) or those with progressive disease ($M = 544.33$) ($F(3) = 2.534$, $p = 0.061$). Specific IgE levels tended to be higher in progressive disease (8.61 kU/l) compared to cured (2.01 kU/l) patients and those stable with (1.92 kU/l) and without BMZ therapy (1.52 kU/l), however, this result was not significant ($F(3) = 2.336$, $p = 0.081$).

Multivariate analysis
To evaluate the effect on the clinical status while adjusting for confounders and interactions between variables, a multivariate analysis was conducted. Two models, one for progressive disease at any point in time and one for cured disease at baseline were designed. Since there was a strong correlation between cytokines, IL-8, IL-10 and CCL20 had to be removed from the model because of multicollinearity (variance inflation factor $VIF > 10.0$). Since specific IgE and total IgE as well as Em2+ and *Echinococcus* IgG IHA correlated strongly, the variable which led to highest increase in $R^2$ was added to the model. Age and gender were added as effect modifiers. Prior to the multivariate analysis, multiple imputation was performed to adjust for missing dependant variables. Both models are displayed in Table 11.

### Table 10. Pearson’s correlations of cytokine and chemokine levels observed in AE patients are shown. $r =$ Pearson’s $r$, $p =$ significance level with * considered significant.

| Cytokine/Chemokine | IL-8 | IL-9 | IL-10 | MCP-4 (CCL13) | TARC (CCL17) | PARC (CCL18) |
|--------------------|------|------|-------|---------------|--------------|--------------|
| IL-9               |      |      |       |               |              |              |
| $r$                |      | -0.01|       |               |              |              |
| $p$                |      | 0.994|       |               |              |              |
| IL-10              |      |      |       |               |              |              |
| $r$                |      | 0.013| 0.645 |               |              |              |
| $p$                |      | 0.893| <0.001|               |              |              |
| MCP-4 (CCL13)      |      |      |       |               |              |              |
| $r$                |      | 0.019| 0.667 | 0.877         |              |              |
| $p$                |      | 0.843| <0.001*| <0.001*       |              |              |
| TARC (CCL17)       |      |      |       |               |              |              |
| $r$                |      | 0.037| 0.425 | 0.777         | 0.723        |              |
| $p$                |      | 0.706| <0.001*| <0.001*       | <0.001*      |              |
| PARC (CCL18)       |      |      |       |               |              |              |
| $r$                |      | 0.043| 0.091 | -0.110        | 0.001        | 0.010        |
| $p$                |      | 0.660| 0.354 | 0.256         | 0.993        | 0.921        |
| LARC (CCL20)       |      |      |       |               |              |              |
| $r$                |      | 0.013| 0.568 | 0.975         | 0.833        | 0.776        | -0.151       |
| $p$                |      | 0.894| <0.001*| <0.001*       | <0.001*      | <0.001*      | 0.121        |

[https://doi.org/10.1371/journal.pntd.0010099.t010](https://doi.org/10.1371/journal.pntd.0010099.t010)
Young age at first clinical presentation and high levels of specific IgE were significant risk factors to develop progressive disease. With every unit the specific IgE increases, the odds for progressive disease increase 1.3-fold. Similarly, the odds increase 1.1-fold with every decreasing year of age at baseline, e.g. at first presentation. High levels of CCL17 might also indicate progressive disease; however, the result missed the required significant level. Low or undetectable antibodies against Em2+ were significantly associated with being cured.

**Discussion**

This study investigated the dynamics of *E. multilocularis* specific and systemic antibody and cytokine and chemokine levels, and, parasite-specific cellular responses during treatment of AE patients. The *E. multilocularis* antigen specific IgE and IgG reactivity and the systemic and parasite-specific cellular cytokine and chemokine responses were differentially expressed with the clinical state of disease. Most AE patients have experienced a state of disease with progressive parasite growth associated with high IgG4 responses [38]. IgG4 production is maintained by chronic helminth infection and supported by Th2-type cytokine responses [39,40]. In AE patients in whom larval lesions have regressed after partial surgical resection of parasite infested tissues or organ, remnants of the laminate layer of *E. multilocularis* may persist for many years and continue to stimulate specific IgG [41,42]. Our results demonstrate a rapid decrease in antibodies against Em2+, especially in cured patients; these antibodies remained negative, making them a significant predictor for cured AE. Previously observed, in patients after curative surgery, seroreversion in the Em2+ ELISA indicated successful resection of lesions in AE patients [41]. Antibodies directed against *E. multilocularis* crude antigens were detectable longer than antibodies directed against the recombinant Em18 antigen in all patient cohorts and stages with 95% sensitivity [42]. The IgG4 responses were similar in patients with vital/progressive and stable >60years disease, and only with cure, the IgG4 reactivity diminished significantly. Furthermore, in patients with stable disease, the IgG4 reactivity increased with age, indicating that inactive or residual cestode antigens will continue to stimulate IgG4. Em2 is a major carbohydrate antigen located on the laminated layer of metacestode larvae. Em2 inhibited polyclonal or parasite extract-induced splenocyte proliferation and triggered IgG3 responses, and together with the related carbohydrate rich Em492 both may contribute to immunosuppressive events and facilitate parasite survival [43,44]. With repeated longitudinal follow up of the *E. multilocularis*-specific antibody isotype responses, the objective would be to detect changes in AE disease activity that is not visible by imaging techniques. This

---

| Table 11. Logistic regression models with variables associated with progressive or cured AE clinical status. OR = Odds, CI 95% = 95% confidence interval, \( p \) = significance level with * considered significant. |
|----------|----------|----------|----------|----------|----------|
| **Variable** | ** Progressive AE** | | | ** Cured AE** | |
| | **OR** | **CI 95%** | **\( p \)** | **OR** | **CI 95%** | **\( p \)** |
| Age | 0.926 | 0.866–0.991 | 0.026* | 0.955 | 0.903–1.011 | 0.112 |
| Sex | 0.871 | 0.122–6.212 | 0.891 | 0.323 | 0.064–1.632 | 0.172 |
| Em2+ antibodies | n.a. | 0.000–n.a. | 0.998 | 0.155 | 0.026–0.910 | 0.039* |
| IgG4 EmAg | 0.996 | 0.963–1.031 | 0.827 | 1.000 | 0.988–1.002 | 0.995 |
| WBC | 0.989 | 0.976–1.002 | 0.107 | 1.002 | 0.999–1.004 | 0.198 |
| Specific IgE | 1.245 | 1.018–1.523 | 0.033* | 0.562 | 0.150–2.101 | 0.386 |
| IL-9 | 1.005 | 0.994–1.017 | 0.372 | 1.002 | 0.991–1.012 | 0.742 |
| MCP-4(CCL13) | 0.992 | 0.982–1.002 | 0.126 | 0.996 | 0.990–1.003 | 0.276 |
| TARC(CCL17) | 1.002 | 1.000–1.004 | 0.076 | 0.997 | 0.993–1.002 | 0.248 |
| PARC(CCL18) | 1.000 | 1.000–1.000 | 0.222 | 1.000 | 1.000–1.000 | 0.261 |

https://doi.org/10.1371/journal.pntd.0010099.t011
requires long term biobanking of patients’ samples and repeated serological analyses. Parallel monitoring with imaging techniques and Em-specific IgE, IgG isotypes and Em2+ reactivity could therefore maximize diagnostic accuracy and inform treatment decisions.

Most AE patients were at stable AE and may remain such for life, while individuals in whom larval tissues regressed and parasite lesions calcified were considered immune competent to control AE progression [11]. Patients with Th1 dominant immune response were more likely to show a curative course of the disease, and Th2 responses were more frequently observed with progressive and vital larval growth [17]. In AE patients, the CD4+ T cell responses weakened over time, and the expansion of regulatory T cells (Treg) was considered an important factor in the immune evasion of *E. multilocularis* [12,14,24]. In experimentally *E. multilocularis* inoculated mice, the T cell responses were increasingly suppressed with parasite persistence, and depletion of FoxP3+ regulatory T cells as immunotherapy against either *E. multilocularis* oral infection with eggs or intraperitoneal injection of larvae, resulted in significantly smaller parasite lesions in the livers and lower parasite loads, respectively [45,46]. The balance between T cell response and parasite load determines the disease outcome of mice infected with different *E. multilocularis* inocula [47]; and a stronger expression of programmed cell-death receptors (PDCD1, 2B4 and LAG3) associated with “exhausted” parasite antigen induced T cell responses and an enhanced *E. multilocularis* metacestode growth at the late stages of infection [47]. In the present work, the Th1-type cytokine IFN-γ production was lower in EmAg-stimulated PBMC from patients with active and stable AE, and IFN-γ responsiveness enhanced with cured AE. Interestingly, therapy with IFN-γ bolus injection was applied to stop AE, and disease progression was not detected during the observed period of 18 months [48]. The injected IFN-γ did not change the TH-2 dominated immune response profile to *E. multilocularis*, but intracellular IL-10 was elevated [48].

In the sera of AE patients with progressive and stable AE, low concentrations of IL-8 (CXCL8) were measured, and concentrations enhanced with cured AE and at year 10 of study. A substantial IL-8 production was observed when granulocytes of AE patients were stimulated with EmAg [35,36] while PBMC released only low amounts. The neutrophil-activating interleukin 8 (CXCL8) will trigger inflammatory responses, and angiogenesis and capillary tube formation are supported by IL-8(CXCL8) [49]. IL-8 is mainly active in primary innate responses and a lessened neutrophil-activating chemokine IL-8(CXCL8) cellular production may silence effector cell migration into *E. multilocularis*-infested tissues and favour parasite persistence. At year 10 of follow up, the serum levels of IL-8 enhanced, and increased angiogenic activity around *E. multilocularis* metacestode larvae may favour chemo attraction of effector granulocytes and trigger cytotoxic responses.

The T helper-type 9 subgroup (TH9) will produce IL 9 in large amounts, together with IL-4, IL-5 or IL-13, and IL-9 can suppress Th1-type cells and support intestinal parasite expulsion, as well as tissue renewal [27,50]. In patients with cystic echinococcosis, enhanced IL-9 concentrations and mRNA levels of TH9-type cells were detected when compared to controls [51]. In this study, IL-9 serum concentrations were similar in the AE patient groups, but at year 10 of study, levels of IL-9 and regulatory IL-10 diminished, suggesting a re-activation of Th1-type immune responses. The positive associations of IL-9 (p<0.001) with several studied cytokines and chemokines disclosed the gradual switch towards a Th1-type responsiveness.

IL-10 exerts anti-inflammatory effects during infections. It regulates and dampens immune responses against pathogens, thus circumventing inflammatory processes which may damage host tissues [52,53]. Regulatory T cell responses and IL-10 with AE are considered to play an important role in parasite tolerance [27] and an increased basal IL-10 secretion was found in patients with progressive AE [23]. Similarly, we detected lowest serum IL-10 with progressive AE, but IL-10 was similarly inducible in vital/progressive, stable, and cured AE cases,
supporting persistent regulatory processes which may counteract inflammation and tissue damage. A spontaneous release of IL-10 by PBMC is considered a sign for a progressive course of the disease, and suppression of the innate immune response induced by IL-10 could promote parasite growth and survival. The positive associations of IL-10 (p<0.001, paired sample correlation) with all studied cytokines and chemokines disclosed its broad regulatory function on T-helper-cell subsets and highlighted IL-10 as a regulator of cellular responsiveness. The IL-10 production appears favourable for parasite persistence and T-helper-cell responses regulated by IL-10 and TGF-β may dampen proinflammatory Th1- and Th2-cells, thereby preventing pathogenic cellular hyperreactivity in AE patients.

The induction of the activation regulated chemokines TARC and PARC and the monocyte chemoattractant MCP-1 after stimulation of PBMCs with EmAg was lowest in stable and cured AE patients, which can be attributed to a suppressed or arrested proliferative growth of the metacestode larvae, possibly supported by long-term therapeutic interventions with benzimidazole. MCP-1 rather contributes to Th2 than to Th1 cytokine-mediated granulomatous inflammation and Th1 cell expansion [54]. The CC-chemokines MCP-3 and MCP-4 were similar in the patient groups making these chemokines less suitable as predictive disease marker [35]. The Th2-type chemokine TARC(CCL17) mediates chemotactic effects on macrophages, monocytes, and eosinophil and basophil granulocytes [55]. Levels of TARC are particularly elevated in inflammatory Th2-type responses with various skin diseases such as atopic dermatitis, bullous pemphigoid, or mycosis fungoides, especially during the acute phases [56]. In patently helminth-infested patients, the serum levels of TARC were strongly increased [57,58], and even higher in helminth and protozoa poly-parasite infections [59]. Levels of CCL17 decreased during treatment, especially in cured AE patients, and CCL17 might serve as a predictive or risk factor for progressive disease.

In AE patients, serum levels of the pulmonary and activation regulated chemokine PARC (100–500 ng/ml) and its cellular production was largely above the other cytokines and chemokines. PARC(CCL18) levels did not change with AE and were not correlated the other tested parameters. PARC(CCL18) is constitutively expressed in the lung and elevated concentrations are detected in pulmonary fibrosis [60,61].

The liver and activation regulated LARC(CCL20) exerts a chemotactic effect on immature dendritic cells (DC), effector/memory T-cells and B-cells, and Th17 cells [62]. LARC(CCL20) can induce migration of dendritic cells through the epithelial tissue to stimulate maturation and proliferation of T and B cells [63]. In *Trichuris muris* infection of mice, dendritic cell recruitment mediated by LARC(CCL20) and RANTES(CCL5) will determine immunity or chronic disease progression [64]. CCL20 contributes to the progression of many cancers, such as liver cancer, colon cancer, breast cancer, pancreatic cancer, and gastric cancer [65]. LARC (CCL20) and its sole receptor CCR6 will favour migration of Treg cells into a tumour microenvironment and disease progression in hepatocellular carcinoma [66]. Increased levels were detected in childhood with proliferative acute lymphoblastic leukemia [67] and LARC will promote cell metastatic spread in human colorectal malignancies [68]. The serum levels of LARC (CCL20) correlated positive with IL-9, IL-10, MCP-1(CCL13) and TARC(CCL17) disclosing their collective role on the expression of innate immune responses. Vital *E. multilocularis* larval tissues or residual not resolved parasite lesions may have stimulated their production, whether these chemokines affected larval growth remains uncertain, but they may serve as markers for AE staging.

In summary, the rapid decrease of antibodies against Em2+, especially in cured patients, makes them a significant predictor for cured AE. The positive relation of *E. multilocularis* specific IgG4 responses with chemokine TARC can indicate AE progression when both enhance over time. Inflammatory and regulatory cytokines and chemokines persisted in AE patients
without an exclusive dominance of Th1-, Th2-, and Treg-type immune responsiveness. Enhanced levels of IL-8, IL-10, MCP4 and LARC may predict AE regression. Repeated biomarker surveys are advisable to evaluate progression or regression of AE during longitudinal follow up, and such analyses can support imaging techniques and improve staging of AE patients.

**Author Contributions**

**Conceptualization:** Beate Grüner, Andreas Hillenbrand, Patrick Voßberg, Peter Kern, Carsten Köhler, Peter T. Soboslay.

**Data curation:** Beate Grüner, Lynn Peters, Patrick Voßberg, Jonas Schweiker, Peter T. Soboslay.

**Formal analysis:** Beate Grüner, Lynn Peters, Patrick Voßberg, Jonas Schweiker, Sanne Burkert, Peter T. Soboslay.

**Funding acquisition:** Beate Grüner, Peter Kern, Carsten Köhler, Peter T. Soboslay.

**Investigation:** Beate Grüner, Lynn Peters, Andreas Hillenbrand, Patrick Voßberg, Jonas Schweiker, Elisabeth G. Rollmann, Laura H. Rodriguez, Jasmin Blumhardt, Carsten Köhler, Peter T. Soboslay.

**Methodology:** Beate Grüner, Lynn Peters, Patrick Voßberg, Jonas Schweiker, Elisabeth G. Rollmann, Laura H. Rodriguez, Jasmin Blumhardt, Peter T. Soboslay.

**Project administration:** Beate Grüner, Peter Kern, Carsten Köhler, Peter T. Soboslay.

**Resources:** Beate Grüner, Andreas Hillenbrand, Peter Kern, Carsten Köhler, Peter T. Soboslay.

**Software:** Beate Grüner, Lynn Peters, Patrick Voßberg, Carsten Köhler, Peter T. Soboslay.

**Supervision:** Beate Grüner, Lynn Peters, Patrick Voßberg, Peter Kern, Carsten Köhler, Peter T. Soboslay.

**Validation:** Beate Grüner, Lynn Peters, Patrick Voßberg, Jonas Schweiker, Elisabeth G. Rollmann, Laura H. Rodriguez, Jasmin Blumhardt, Sanne Burkert, Carsten Köhler, Peter T. Soboslay.

**Visualization:** Beate Grüner, Patrick Voßberg, Jonas Schweiker, Elisabeth G. Rollmann, Laura H. Rodriguez, Jasmin Blumhardt, Carsten Köhler, Peter T. Soboslay.

**Writing – original draft:** Beate Grüner, Lynn Peters, Patrick Voßberg, Jonas Schweiker, Sanne Burkert, Carsten Köhler, Peter T. Soboslay.

**Writing – review & editing:** Beate Grüner, Lynn Peters, Sanne Burkert, Peter T. Soboslay.

**References**

1. Peters L, Burkert S, Grüner B. Parasites of the liver—epidemiology, diagnosis, and clinical management in the European context. J Hepatol 2021; 75:202–218. [https://doi.org/10.1016/j.jhep.2021.02.015](https://doi.org/10.1016/j.jhep.2021.02.015) PMID: 33636243

2. Wen H, Vuitton L, Tuxun T, Li J, Vuitton DA, Zhang W, et al. Echinococcosis: Advances in the 21st Century. Clin Microbiol Rev 2019; 32:e00075–18. [https://doi.org/10.1128/CMR.00075-18](https://doi.org/10.1128/CMR.00075-18) PMID: 30760475

3. Grüner B, Kern P, Mayer B, Gräter T, Hillenbrand A, Barth TEF, et al. Comprehensive diagnosis and treatment of alveolar echinococcosis: A single-center, long-term observational study of 312 patients in Germany. GMS Infect Dis 2017; 5: Doc01. [https://doi.org/10.3205/id000027](https://doi.org/10.3205/id000027) PMID: 30871329
4. Lötsch F, Budke CM, Auer H, Kaczirek K, Wanecek F, Lagler H, et al. Evaluation of direct costs associated with alveolar and cystic echinococcosis in Austria. PLoS Negl Trop Dis 2019; 13:e0007110. https://doi.org/10.1371/journal.pntd.0007110 PMID: 30703091

5. Kern P, Menezes da Silva A, Akhan O, Müllhaupt B, Vizaychhipa KA, Budke C, et al. The Echinococcoses: Diagnosis, Clinical Management and Burden of Disease. Adv Parasitol 2017; 96:259–369. https://doi.org/10.1016/bs.apar.2016.09.006 PMID: 28212790

6. Menezes da Silva A. M. Human Echinococcosis: A Neglected Disease. Gastroenterol Res Pract 2010; 2010:583297. https://doi.org/10.1155/2010/583297 PMID: 20862339

7. Craig PS, Heggin D, Lightowlers MW, Torgerson PR, Wang Q. Echinococcosis: Control and Prevention. Adv Parasitol 2017; 96:55–158. https://doi.org/10.1016/bs.apar.2016.09.002 PMID: 28212791

8. Torgerson PR, Keller K, Magnotta M, Ragland N. The Global Burden of Alveolar Echinococcosis. PLoS Negl Trop Dis 2010; 4:e724. https://doi.org/10.1371/journal.pntd.0000722 PMID: 20582310

9. Vuitton DA, Demonemrot F, Knapp J, Richou C, Grenouillet F, Chauchet A, et al. Clinical epidemiology of human AE in Europe. Vet Parasitol 2015; 21:110–20.

10. Deplazes P, Rinaldi L, Alvarez Rojas CA, Torgerson PR, Harandi MF, Romig T, et al. Global Distribution of Alveolar and Cystic Echinococcosis. Adv Parasitol 2017; 95:315–493. https://doi.org/10.1016/bs.apar.2016.11.001 PMID: 28131365

11. Gottstein B, Felleisen R. Protective immune mechanisms against the metacestode of Echinococcus multilocularis. Parasitol Today 1995; 11:320–6. https://doi.org/10.1016/0169-4758(95)80184-7 PMID: 15275313

12. Pan W, Xu HW, Hao WT, Sun FF, Qin YF, Hao SS, et al. The excretory-secretory products of Echinococcus granulosus protoscoleces stimulated IL-10 production in B cells via TLR-2 signaling. BMC Immunol 2018; 19:29. https://doi.org/10.1186/s12865-018-0267-7 PMID: 30355335

13. Pittini A, Martínez-Acosta YE, Casaravilla C, Seoane PI, Rückerl D, Quijano C, et al. Particles from the Echinococcus granulosus Laminated Layer Inhibit CD40 Upregulation in Dendritic Cells by Interfering with Akt Activation. Infect Immun 2019; 87:e00641–19. https://doi.org/10.1128/IAI.00641-19 PMID: 31570562

14. Wang J, Gottstein B. Immunoregulation in larval Echinococcus multilocularis infection. Parasite Immunol 2016; 38:182–92. https://doi.org/10.1111/j.1229 PMID: 26536823

15. Díaz A, Casaravilla C, Allen JE, Sim RB, Ferreira AM. Understanding the laminated layer of larval Echinococcus II: immunology. Trends Parasitol 2011; 27:264–73. https://doi.org/10.1016/j.pt.2011.01.008 PMID: 21376669

16. Wellinghausen N, Gebert P, Kern P. Interleukin (IL)-4, IL-10 and IL-12 profile in serum of patients with alveolar echinococcosis. Acta Trop 1999; 73:165–74. https://doi.org/10.1016/s0001-706x(99)00027-3 PMID: 10465056

17. Godot V, Harraga S, Beurton I, Deschaseaux M, Sarciron E, Gottstein B, et al. Resistance/susceptibility to Echinococcus multilocularis infection and cytokine profile in humans. I. Comparison of patients with progressive and abortive lesions. Clin Exp Immunol 2000; 121:484–90. https://doi.org/10.1046/j.1365-2249.2000.01308.x PMID: 10971515

18. Sturm D, Menzel J, Gottstein B, Kern P. Interleukin-5 is the predominant cytokine produced by peripheral blood mononuclear cells in alveolar echinococcosis. Infect Immun 1995; 63:1688–97. https://doi.org/10.1128/iai.63.5.1688-1697.1995 PMID: 7729873

19. Gottstein B, Soboslay P, Ortona E, Wang J, Siracusano A, Vuitton DA. Immunology of Alveolar and Cystic Echinococcosis (AE and CE). Adv Parasitol 2017; 96:1–54. https://doi.org/10.1016/bs.apar.2016.09.005 PMID: 28212788

20. Gottstein B, Hemphill A. Immunopathology of echinococcosis. Cem. Immunol., 1997; 66:177–208. https://doi.org/10.1111/j.00058670 PMID: 9103670

21. Harraga S, Godot V, Bresson-Hadni S, Manton G, Vuitton DA. Profile of cytokine production within the periparasitic granuloma in human alveolar echinococcosis. Acta Trop 2000; 85:231–6. https://doi.org/10.1016/s0001-706x(02)00218-8 PMID: 12606101

22. Conchedda M, Gabriele E, Bortolletti G. Immunobiology of cystic echinococcosis. Parassitologia 2004; 46(4):375–380. PMID: 16044694

23. Godot V, Harraga S, Deschaseaux M, Bresson-Hadni S, Gottstein B, Emile D. Increased basal production of interleukin-10 by peripheral blood mononuclear cells in human alveolar echinococcosis. Eur Cytokine Netw 1997; 8:401–8. PMID: 9459621

24. Harraga S, Godot V, Bresson-Hadni S, Manton G, Vuitton DA. Profile of cytokine production within the periparasitic granuloma in human alveolar echinococcosis. Acta Trop 2003; 85:231–6. https://doi.org/10.1016/s0001-706x(02)00218-8 PMID: 12606101
25. Bresson- Hadni S, Vuitton DA, Lenys D, Liance M, Racodot E, Miguel JP. Cellular immune response in *Echinococcus multilocularis* infection in humans. I. Lymphocyte reactivity to Echinococcus antigens in patients with alveolar echinococcosis. Clin Exp Immunol 1989; 78:61–6. PMID: 2805424

26. Vuitton DA, Zhang SL, Yang Y, Godot V, Beurton I, Mantion G. et al. Survival strategy of *Echinococcus multilocularis* in the human host. Parasitol Int. 2006; 55 Suppl:S51–5. https://doi.org/10.1016/j.parint.2005.11.007 PMID: 16360335

27. Vuitton DA, Gottstein B. *Echinococcus multilocularis* and its intermediate host: a model of parasite-host interplay. J Biomed Biotechnol. 2010; 2010:923193. https://doi.org/10.1155/2010/923193 PMID: 20339517

28. Kern P, Wen H, Sato N, Vuitton DA, Gruener B, Shao Y, et al. WHO classification of alveolar echinococcosis: principles and application. Parasitol Int 2006; 55 Suppl:S283–7. https://doi.org/10.1016/j.parint.2005.11.041 PMID: 16349385

29. Schmidberger J, Kratzer W, Stark K, Grüner B; Echinococcosis Working Group. Alveolar echinococcosis in Germany, 1992–2016. An update based on the newly established national AE database. Infection 2018; 46:197–206. https://doi.org/10.1007/s15100-017-1094-0 PMID: 29090421

30. Brunetti E, Kern P, Vuitton DA. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 2010; 114:1–16. https://doi.org/10.1016/j.actatropica.2009.11.001 PMID: 19931502

31. Graeter T, Eberhardt N, Shi R, Schmidberger J, Beer AJ, Beer M, et al. Hepatic alveolar echinococcosis: correlation between computed tomography morphology and inflammatory activity in positron emission tomography. Sci Rep 2020; 10:11808. https://doi.org/10.1038/s41598-020-68624-9 PMID: 32678174

32. Reiter-Owona I, Grüner B, Frosch M, Hoerauf A, Kern P, Tappe D. Serological confirmatory testing of alveolar and cystic echinococcosis in clinical practice: results of a comparative study with commercialized and in-house assays. Clin Lab 2009; 55:41–8. PMID: 19350848

33. Wellinghausen N, Kern P. A new ImmunoCAP assay for detection of *Echinococcus multilocularis*-specific IgE. Acta Trop. 2001; 79:123–7. https://doi.org/10.1016/s0001-706x(01)00087-0 PMID: 11369304

34. Huang X, Grüner B, Lechner CJ, Kern P, Soboslay PT. Distinctive cytokine, chemokine, and antibody responses in *Echinococcus multilocularis*-infected patients with cured, stable, or progressive disease. Med Microbiol Immunol 2014; 203:185–93. https://doi.org/10.1007/s00430-014-0331-8 PMID: 24509604

35. Kocherscheidt L, Flakowski AK, Grüner B, Hamm DM, Dietz K, Kern P, et al. *Echinococcus multilocularis*: inflammatory and regulatory chemokine responses in patients with progressive, stable and cured alveolar echinococcosis. Exp Parasitol 2008; 119:467–74. https://doi.org/10.1016/j.exppara.2008.04.006 PMID: 18490012

36. Eger A, Kirch A, Manfras B, Kern P, Schulz-Key H, Soboslay PT. Pro-inflammatory (IL-1beta, IL-18) cytokines and IL-8 chemokine release by PBMC in response to *Echinococcus multilocularis* metacestode vesicles. Parasite Immunol 2003; 25:103–5. https://doi.org/10.1046/j.1365-3024.2003.00601.x PMID: 12791106

37. Newgard CD, Haukoos JS. Advanced Statistics: Missing Data in Clinical Research—Part 2: Multiple Imputation. Acad Emerg Med 2007; 14:669–78. https://doi.org/10.1197/j.aem.2006.11.038 PMID: 17599227

38. Dreweck CM, Lüder CG, Soboslay PT, Kern P. Subclass-specific serological reactivity and IgG4-specific antigen recognition in human echinococcosis. Trop Med Int Health. 1997; 2:779–87. https://doi.org/10.1046/j.1365-3156.1997.d01-385.x PMID: 9294548

39. Figueiredo CA, Barreto ML, Rodrigues LC, Cooper PJ, Silva NB, Amorim LD, et al. Chronic intestinal helminth infections are associated with immune hyporesponsiveness and induction of a regulatory network. Infect Immun. 2010; 78:3160–7. https://doi.org/10.1128/IAI.01228-09 PMID: 20404082

40. Geiger SM, Massara CL, Bethony J, Soboslay PT, Carvalho OS, Corrêa-Oliveira R. Cellular responses and cytokine profiles in Ascaris lumbricoides and *Trichuris trichiura* infected patients. Parasite Immunol 2002; 24:499–509. https://doi.org/10.1046/j.1365-3024.2002.00600.x PMID: 12694600

41. Tappe D, Frosch M, Sako Y, Itoh S, Grüner B, Reuter S, et al. Close relationship between clinical regression and specific serology in the follow-up of patients with alveolar echinococcosis in different clinical stages. Am J Trop Med Hyg 2009; 80:792–7. PMID: 19407126

42. Tappe D, Sako Y, Itoh S, Frosch M, Grüner B, Kern P, et al. Immunoglobulin G subclass responses to recombinant Em18 in the follow-up of patients with alveolar echinococcosis in different clinical stages. Clin Vaccine Immunol 2010; 17:944–8. https://doi.org/10.1128/CVI.00026-10 PMID: 20392888

43. Dai WJ, Hemphill A, Waldvogel A, Ingold K, Deplazes P, Mossmann H, et al. Major carbohydrate antigen of *Echinococcus multilocularis* induces an immunoglobulin G response independent of alpha beta+
Walker M, Baz A, Dematteis S, Stettler M, Gottstein B, Schaller J, et al. Isolation and characterization of
44. W...
62. Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003; 14:409–26. https://doi.org/10.1016/s1359-6101(03)00049-2 PMID: 12948524

63. Kadomoto S, Izumi K, Mizokami A. The CCL20-CCR6 Axis in Cancer Progression. Int J Mol Sci 2020; 21: E5186. https://doi.org/10.3390/ijms21155186 PMID: 32707869

64. Cruickshank SM, Deschoolmeester ML, Svensson M, Howell G, Bazakou A, Logunova L, et al. Rapid dendritic cell mobilization to the large intestinal epithelium is associated with resistance to *Trichuris muris* infection. J Immunol 2009; 182:3055–62. https://doi.org/10.4049/jimmunol.0802749 PMID: 19234202

65. Chen W, Qin Y, Liu S. CCL20 Signalling in the Tumor Microenvironment. Adv Exp Med Biol 2020; 1231:53–65. https://doi.org/10.1007/978-3-030-36667-4_6 PMID: 32060846

66. Chen KJ, Lin SZ, Zhou L, Xie HY, Zhou WH, Taki-Eldin A, et al. Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumour progression and predicts poor prognosis. PLoS One. 2011; 6:e24671. https://doi.org/10.1371/journal.pone.0024671 PMID: 21935436

67. Struyf S, Schutyser E, Gouwy M, Gijsbers K, Proost P, Benoit Y, et al. PARC/CCL18 is a plasma CC chemokine with increased levels in childhood acute lymphoblastic leukemia. Am J Pathol 2003; 163:2065–75. https://doi.org/10.1016/S0002-9440(10)63564-X PMID: 14578205

68. Frick VO, Rubic C, Keilholz U, Ghadjar P. Chemokine/chemokine receptor pair CCL20/CCR6 in human colorectal malignancy: An overview. World J Gastroenterol 2016; 22:833–41. https://doi.org/10.3748/ wjg.v22.i2.833 PMID: 26811629